Abstract
Infections caused by hepatitis C virus (HCV) are a significant worldwide health problem for which novel therapies are urgently needed. One attractive and viable therapeutic target is HCV NS5B RNA dependent RNA polymerase (RdRp) since it is essential for the replication of the viral genome of HCV. The hunt for nonnucleoside inhibitors (NNIs) of HCV NS5B polymerase has led to the identification of several allosteric pockets. However, because the topographical features of these binding sites vary across and even within diverse HCV genotypes, the discovery of new antiviral drugs capable of inhibiting HCV RdRp in the face of variable binding pockets becomes a challenging endeavor. This review focuses on recent accomplishments in the development of new NNIs of HCV NS5B polymerase and on their binding mechanisms to the respective allosteric pockets. Potential difficulties surrounding the discovery of future NNIs targeted to different allosteric pockets of HCV NS5B and to HCV NS5B from different genotypes are also discussed.
Keywords: HCV NS5B polymerase, Allosteric pocket, Nonnucleoside inhibitors, Genotypes, Structure activity relationships
Current Bioactive Compounds
Title: Multiple Allosteric Pockets of HCV NS5B Polymerase and its Inhibitors: A Structure Based Insight
Volume: 4 Issue: 2
Author(s): Tanaji T. Talele
Affiliation:
Keywords: HCV NS5B polymerase, Allosteric pocket, Nonnucleoside inhibitors, Genotypes, Structure activity relationships
Abstract: Infections caused by hepatitis C virus (HCV) are a significant worldwide health problem for which novel therapies are urgently needed. One attractive and viable therapeutic target is HCV NS5B RNA dependent RNA polymerase (RdRp) since it is essential for the replication of the viral genome of HCV. The hunt for nonnucleoside inhibitors (NNIs) of HCV NS5B polymerase has led to the identification of several allosteric pockets. However, because the topographical features of these binding sites vary across and even within diverse HCV genotypes, the discovery of new antiviral drugs capable of inhibiting HCV RdRp in the face of variable binding pockets becomes a challenging endeavor. This review focuses on recent accomplishments in the development of new NNIs of HCV NS5B polymerase and on their binding mechanisms to the respective allosteric pockets. Potential difficulties surrounding the discovery of future NNIs targeted to different allosteric pockets of HCV NS5B and to HCV NS5B from different genotypes are also discussed.
Export Options
About this article
Cite this article as:
Talele T. Tanaji, Multiple Allosteric Pockets of HCV NS5B Polymerase and its Inhibitors: A Structure Based Insight, Current Bioactive Compounds 2008; 4 (2) . https://dx.doi.org/10.2174/157340708785294217
DOI https://dx.doi.org/10.2174/157340708785294217 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Suitable Antibacterial Substances for the Treatment of Urinary Tract Infections
Anti-Infective Agents in Medicinal Chemistry Implications of VIP and PACAP in Parkinson’s Disease: What do we Know So Far?
Current Medicinal Chemistry Oral Mucosal Immunization: Recent Advancement and Future Prospects
Current Immunology Reviews (Discontinued) Catatonia Due to a General Medical Condition (Organic Catatonia)
Current Psychiatry Reviews Melatonin Causes Gene Expression in Aged Animals to Respond to Inflammatory Stimuli in a Manner Differing from that of Young Animals
Current Aging Science α7 Nicotinic Receptor Agonists as Potential Therapeutic Drugs for Schizophrenia
Current Medicinal Chemistry - Central Nervous System Agents Elucidating the Pivotal Role of Immune Players in the Management of COVID-19: Focus on Mesenchymal Stem Cells and Inflammation
Current Stem Cell Research & Therapy Anti-IL-12/23 in Crohn's Disease: Bench and Bedside
Current Drug Targets The Role of the Endothelium in the Pathogenesis of Atherosclerosis and its Therapeutic Implications
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies
Current Drug Targets Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Anti-Angiogenic Treatment for Exudative Age-Related Macular Degeneration: New Strategies are Underway
Current Angiogenesis (Discontinued) Recent Developments of Magnetic Nanoparticles for Theranostics of Brain Tumor
Current Drug Metabolism Endothelial Dysfunction, Impaired Endogenous Platelet Inhibition and Platelet Activation in Diabetes and Atherosclerosis
Current Vascular Pharmacology Myostatin Inhibition and Cardiometabolic Disorders
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Imidazoles as Promising Scaffolds for Antibacterial Activity: A Review
Mini-Reviews in Medicinal Chemistry Palifermin in theManagement of Mucositis in Hematological Malignancies: Current Evidences and Future Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry Safety and Efficacy of Tocolytics for the Treatment of Spontaneous Preterm Labour
Current Pharmaceutical Design A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer
Current Topics in Medicinal Chemistry Sphingosine 1-Phosphate in Vascular Biology: Possible Therapeutic Strategies to Control Vascular Diseases
Current Pharmaceutical Design